VNA
CRSP icon

Valley National Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Valley National Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.5K Sell
1,000
-100
-9% -$5.27K 0.01% 397
2026
Q1 		$52K Hold
1,100
– – 0.01% 402
2025
Q4 		$57K Buy
1,100
+100
+10% +$5.99K 0.01% 384
2025
Q3 		$64K Hold
1,000
– – 0.01% 357
2025
Q2 		$48K Hold
1,000
– – 0.01% 382
2025
Q1 		$34K Hold
1,000
– – 0.01% 419
2024
Q4 		$39K Hold
1,000
– – 0.01% 379
2024
Q3 		$46K Sell
1,000
-100
-9% -$5.07K 0.01% 362
2024
Q2 		$59K Hold
1,100
– – 0.01% 369
2024
Q1 		$74K Buy
1,100
+100
+10% +$7.16K 0.01% 357
2023
Q4 		$62K Buy
+1,000
New +$55.3K 0.01% 376

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Valley National Advisers's CRSP Position: Q2 2026 in Review

Valley National Advisers reduced its CRISPR Therapeutics (CRSP) stake by 9.1% in Q2 2026, selling an estimated $5.27K and leaving 1,000 shares worth $54.5K. The position accounts for 0.01% of the portfolio, ranked #397.

Valley National Advisers first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $74K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Valley National Advisers held 1,000 shares of CRISPR Therapeutics worth $54.5K as of Q2 2026.
  • Valley National Advisers sold 100 CRISPR Therapeutics shares in Q2 2026, an estimated $5.27K.
  • CRISPR Therapeutics made up 0.01% of Valley National Advisers's portfolio in Q2 2026, its #397 holding.
  • Valley National Advisers first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Valley National Advisers's CRISPR Therapeutics position peaked at $74K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.